Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN,…
Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the dramatic and exciting approach of using CAR T-cells to…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN,…
Pierluigi Porcu, MD, from the Sidney Kimmel Cancer Center, Philadelphia, PA, discusses recent clinical developments that have provided healthcare professionals…
While mantle cell lymphoma (MCL) can be an aggressive disease, there is a subgroup of patients whose disease poses low…
With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the…
With cutaneous T-cell lymphoma (CTCL) being a rare disease with an incredibly high prevalence, Pierluigi Porcu, MD, from Sidney Kimmel…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center,…
Despite benefits of targeted therapies for genetic mutations in AML, a limitation with this approach is that the mutation may…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham,…
From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC,…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer…
Myeloproliferative neoplasms, a group of blood disorders, have debilitating effects on patients, including shortening life expectancy and lowering the quality…
Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center asks the question why…
Mayer Fishman, MD PhD Dept. of GU Oncology Moffitt Cancer Center Dept. of Oncologic Sciences, USF Morsani College of Medicine…
Chung-Han (Joe) Lee, MD/PhD Memorial Sloan Kettering Cancer Center discusses Novel combinational therapies: Is the increased toxicity worth the possibility…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Systemic treatment…
Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center discusses the best agents for second line…
Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses What is the best…
VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY of UT Southwestern discusses NEOADJUVANT THERAPY PRIOR TO SURGERY at the Kidney Cancer…
Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of…
Susan Demo, Ph.D of Calithera discusses Why should I participate in a clinical trial?? Whats in it for me? at…
Currently, out of all FLT3 inhibitors, only midostaurin is FDA-approved for use in patients with acute myeloid lymphoma (AML). From…
The IDH1 and IDH2 metabolic enzymes are mutated in patients with acute myeloid leukemia (AML), prompting the pharmaceutical development of…
In the last 15 years, there has been a revolution in our understanding of the pathogenesis of acute myeloid lymphoma…
Achieving measurable residual disease (MRD) negativity after completing therapy is an early indicator of overall survival. Presently, MRD testing is…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany,…
Triple combination therapy is the administration of obinutuzumab, ibrutinib, and venetoclax in a sequential order. Barbara Eichhorst from the University…
Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, presents results from clinical trials testing an intensive fludarabine, cyclophosphamide, rituximab…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology at MD Anderson discusses What are…
Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant…
Naomi B Haas MD, Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center September 22, 2018 at the…
E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Management and Outcomes in…
Brian Shuch, MD Associate Professor of Urology Director, Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research…
In this session, Thomas Habermann, MD, of the Mayo Clinic, Rochester, MI, chairs a discussion with Bjoern Chapuy, PhD, MD,…
Immunotherapy is at the forefront of research into novel treatments for lymphoma. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed…
The International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, presented an array of exciting new data…
Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with Anas…
CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including…
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018…
Somatic mutations can be used to inform diagnosis and prognosis, but they are also useful targets for novel therapies. Valeria…
While myelodysplastic syndromes (MDS) represent a heterogeneous set of pathologies, a large proportion of MDS show similarity in somatic mutations.…
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here,…
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing…
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to…
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent…
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University…
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Simon Rule, MD, from Plymouth University,…
EZH2 mutations are associated with a poor prognosis in myelodysplastic syndromes (MDS). In this video, recorded at the 2018 Society…
Providing us with insight into a trial not yet published, Pierluigi Porcu, MD, from Jefferson Hospital, Sidney Kimmel Cancer Center,…
First line therapies for chronic lymphocytic leukemia (CLL) have developed beyond the historic approach of giving all patients FCR chemoimmunotherapy.…
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug…
Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University…
CAR T-cells have the potential to revolutionize the field of hematological oncology, however despite impressive efficacy data from CAR T…
Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video,…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management…
Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of minimal residual…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Christopher Gibson, MD, of Dana-Farber…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD, of the University…
Speaking at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Nathan Fowler, MD, of The University…
Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial…
DNA sequencing approaches such as next-generation sequencing (NGS) have been found to be particularly useful when diagnosing cancers. These results…
Patients that relapse or are resistant to treatments are classified as high-risk in follicular lymphoma. Here, Nathan Fowler, MD, of…
In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD,…
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the reliability of next-generation sequencing (NGS) at the 2018 Society…
Recent approvals in hepatocellular carcinoma (HCC) have increased the treatment options available for patients with this disease, leading to improved…
BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester,…
Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel…
Understanding the mechanisms of drug resistance in multiple myeloma (MM) is vital in order to improve treatment. In this comprehensive…
Ivan Borrello, MD, of Johns Hopkins University School of Medicine, Baltimore, MD, discusses the role of the microenvironment in multiple…
Is measurable residual disease (MRD) ready for prime time in multiple myeloma (MM)? Gareth Morgan, MD, PhD, FRCP, FRCPath, of…
Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, rounds up the Myeloma 2018 meeting, held in San Diego,…
The experts at the Myeloma 2018 meeting in San Diego, CA, discussed the successes, challenges and future outlook for CAR…
From the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss novel targets in multiple myeloma (MM), including…
The progression to multiple myeloma (MM) in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
In this exciting discussion, the experts explore the prevocative question of ‘is precision medicine a bust in multiple myeloma?’ Topics…
From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute,…
Keith Stewart, MB, ChB from the Mayo Clinic, Rochester, MN, is joined by Kenneth Anderson, MD, of the Dana-Farber Cancer…
CAR T-cells are an exciting new therapeutic area in multiple myeloma (MM). Here, the experts discuss the current landscape of…
CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of…
Treatment of advanced Hodgkin lymphoma has evolved dramatically in the last 10 years, especially with the introduction of PET-response adapted…
Florent Malard, MD, PhD, of Saint Antoine Hospital, Paris, France, discusses potential measures to improve the outcome of transplantation at…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host…
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this…
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, discusses the previous management of chronic graft-versus-host disease…
In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, speaks at the European Society for…
From the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal, Steven Pavletic, MD,…
Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, gives an overview of the management of chronic graft-versus-host…
Treating aplastic anemia (AA) with transplantation in a pediatric population is deemed relatively complicated, according to Régis Peffault de Latour,…
Régis Peffault de Latour, MD, PhD, from Saint Louis Hospital, Paris, France, discusses the main challenges in managing patients with…
From the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Régis Peffault de…
Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Fermin Sanchez-Guijo,…
In this interview, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD,…
Dividing patients into subgroups for different therapies can often be quite difficult. In this interview, recorded at the 2018 European…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Abdul Hamid Bazarbachi,…
In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and…
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights…
Bone metastases are present in the majority of patients with prostate cancer and are the main cause of mortality in…
Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia,…
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia,…
Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
At the Genitourinary Cancers Symposium 2018 in San Francisco, CA, recent therapeutic developments for renal cell carcinoma (RCC) were discussed…
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer…
BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some…
Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination…
Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab…
The use of prostate-specific antigen (PSA) levels as a diagnostic test for prostate cancer has significantly reduced mortality rates, as…
Treatment for muscle-invasive bladder cancer has evolved as medical knowledge has expanded. Jeanny Aragon-Ching, MD, FACP, from Inova Schar Cancer…
Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC,…
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan,…
In this video, Peter Black, MD, of the University of British Columbia, Vancouver, Canada, speaks to us about the use…
Maria Teresa Bourlon, MD, MS, of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, discusses the…
Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA, discusses the differences in survival rates of non-urothelial…
Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Eugene Teoh, MBBS, MRCP, from the University of…
In this video, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, discusses the progress made in prostate, bladder…
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses precision medicine at the European Lung Cancer…
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin)…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD,…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD,…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the…
Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small…
Here, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, outlines the collaborative approach taken by his institution,…
In this video, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, encourages the use of social media,…
Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Khaled Ghanem, MD,…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dean Fennell, PhD, FRCP, of the University of…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, talks about delivering personalized therapy for…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, discusses upcoming therapeutic targets for mesothelioma…
The human papilloma virus (HPV) currently has no cure, with virtually all cases of cervical cancer being caused by HPV.…
From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana…
In this video, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, delivers advice to…
In this video, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, describes how identifying molecular…
The importance of the clinical pharmacy specialist is often understated. Here, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Judith Smith, PharmD, BCOP, CPHQ, FCCP,…
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in…
Fermin Sanchez-Guijo, MD, PhD, of Hospital ClÃnico Universitario de Salamanca, Salmanca, Spain, speaks to us about the role of mesenchymal…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Ernst Holler, MD,…
Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for >30 years, which is used to prevent graft-versus-host disease…
Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Genovefa Papanicolaou,…
Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark, discusses current first-line treatment options in Hodgkin lymphoma at the…
In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, is involved in developing a technique for eradicating…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Denis Claude Roy,…
Antonio Almeida, MD, PhD, of the Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Matti Aapro, MD, of the Clinique de…
New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy…
Decreasing tobacco intake is a key goal for reducing the incidence of lung cancer. In this video, recorded at the…
With the approval of new therapies that are restricted based on PD-L1 expression, there are many different assays to test…
Lung cancer screening is an exciting and debated topic. Here, Mamta Ruparel, MBBS, MRCP, of University College London, London, UK,…
Mamta Ruparel, MBBS, MRCP, of University College London, London, UK, discusses the current data and guidelines associated with the finding…
In recent years, there has been a massive increase in the number of different immunotherapeutic agents that can be used…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Capuzzo, MD, PhD, of AUSL della Romagna,…
In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of…
Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Keith Kerr, MB, ChB, FRCPath, FRCPE, from…
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant…
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate…
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone…
BMIC058
In this video, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, raises the issue of slow progression of clinical trials in acute…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann,…
Here, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Robin Foà ,…
In this video, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses the importance of allogeneic transplant in different…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual…
Prakash Satwani, MD, of Columbia University Medical Center, New York, NY, speaks to us about the true cost of bone…
In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD,…
John P. Fruehauf, MD, UC Irvine Health, Looks at Data from Combination Studies | ASCO 2019 Will Show The Role…
Fa-Chyi Lee, MD, UC Irvine Health, talks about Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine at MOASC…
Edward L. Nelson, MD, UC Irvine Health talks about hoe RET Inhibitors May Be Approved this Year | Systems-Based Approach…
Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the…
John P. Fruehauf, MD, UC Irvine Health, explains New Treatment for Melanoma is Working Everywhere | Working For Metastatic Disease…
Nataliya Mar, MD, UC Irvine Health, talks about Emerging New Agents for Urothelial Carcinoma | Immunotherapies in Metastatic Castration-Resistant Patients…
John P. Fruehauf, MD, UC Irvine Health, Looks at Combinations of Therapies | Combine Targeted BRAF Agents with Immunotherapy at…
Fa-Chyi Lee, MD, UC Irvine Health, talks about a possible Better Approach in the Next 1-2 Years | For RAS…
Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted…
John P. Fruehauf, MD, UC Irvine Health, explains Practice-Changing Impact of Presented Data | Durability to the Benefit of Immunotherapy…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Improving Survival in Stage 4 Breast Cancer | S0226 Showed That…
John P. Fruehauf, MD, UC Irvine Health, explains What to do with Stage 3 Disease | Which is a Better…
Nataliya Mar, MD, UC Irvine Health, talks about Phase 1 Urothelial Carcinoma Data Presented | Combination Therapies in Renal Cell…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Christine Walko, PharmD, BCOP, FCCP, of…
In this interview, David DeRemer, PharmD, BCOP, FCCP, of the University of Florida, Gainesville, FL, discusses mid-career changes that pharmacists…
In this interview, Christine Walko, PharmD, BCOP, FCCP, of the Moffitt Cancer Center, Tampa, FL, speaks about the Moffitt Cancer…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel Wolff, MD,…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, held in Denver, CO, Jill Kolesar, PharmD, MS, BCPS, FCCP,…
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the…
The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment…
The ABACUS trial (NCT02662309), an investigator-initiated Phase II study investigating the safety and efficacy of two cycles of neoadjuvant atezolizumab…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge,…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson,…
With the positive results from recent trials like SPARTAN (NCT01946204) and PROSPER (NCT02003924), it is likely that drugs typically associated…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Robert Figlin,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson,…
After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC)…
Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, discusses single target therapies in thoracic oncology and beyond…
Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates…
In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Avoiding Chemotherapy in Subset of Patients | TAILORx Uses Scoring Method…
Yung Lyou, MD, UC Irvine Health, talks about Weighing Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2…
Edward L. Nelson, MD, UC Irvine Health says to Enroll Patients in Umbrella or Basket Trials | PI3-kinase Did Not…
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
John P. Fruehauf, MD, UC Irvine Health, explains how 50% of Melanoma Patients Develop Brain Metastases | BRAF-MEK & Immunotherapy…
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
Nataliya Mar, MD, UC Irvine Health, talks about Erdafitinib & Enfortumab Reached FDA Drug Designation | Will be Available in…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline…
Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of targeted vs.…
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML).…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock,…
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes…
With the increased use of next-generation sequencing (NGS) to identify mutations in patient’s own cancer cells, the off-label usage of…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ginah Nightingale, PharmD, BCOP, of Thomas…
Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses why cognitive impairment as a result of chemotherapy is…
There is increasing evidence to suggest that chemotherapy contributes to changes in cognition. In this interview, Ginah Nightingale, PharmD, BCOP,…
In this interview, Amy Pick, PharmD, BCOP, of Creighton University, Omaha, NE, speaks about different types of stressors for mid-career…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Amy Pick, PharmD, BCOP, of Creighton…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here,…
VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German…
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Wolfgang Wick, MD, of the…
Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon Health and Science University Hospital, Portland, OR, speaking from the 2018 Hematology/Oncology Pharmacy…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, in Denver, CO, Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon…